22.84 USD
↘ 0.17 (0.76%)PRE MARKET (AS OF 07:02 AM EDT)
Alumis Inc. Common Stock
ALMSNASDAQ • USD
Market: OPEN
Open?$23.15
High?$23.15
Low?$22.70
Prev. Close?$22.87
Volume?133
Avg. Volume?1.1M
VWAP?$23.15
Rel. Volume?0.00x
Bid / Ask
Bid?$19.00 × 100
Ask?$27.07 × 100
Spread?$8.07
Midpoint?$23.04
Valuation & Ratios
Market Cap?2.9B
Shares Out?123.4M
Float?71.1M
Float %?57.7%
P/E Ratio?N/A
P/B Ratio?5.14
EPS?-$1.86
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
Themes
Address
280 EAST GRAND AVENUE
SOUTH SAN FRANCISCO, CA 94080
Phone: 650-231-6625
SOUTH SAN FRANCISCO, CA 94080
Phone: 650-231-6625
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?7.51Strong
Quick Ratio?7.51Strong
Cash Ratio?0.90Adequate
Debt/Equity?0.00Low
ValuationFAIRLY VALUED
Score58/100
P/E?N/A▾
P/B?5.14FAIR▾
P/S?347.03HIGH▾
P/FCF?N/A▾
EV/EBITDA?-6.4CHEAP▾
EV/Sales?339.43HIGH▾
Returns & Efficiency
ROE?-41.9%WEAK▾
ROA?-35.4%WEAK▾
Cash Flow & Enterprise
FCF?$-377030000
Enterprise Value?$2.9B
Fundamentals ratios updated end of day